Arcticzymes Technologies ASA (AZT) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Arcticzymes Technologies ASA NOK 8.52, price NOK 20.30, upside -58.0%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Arcticzymes Technologies ASA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range kr 12.74 – kr 107.40 · fair‑value band kr 7.80 – kr 9.44 · the kr 20.30 price screens above the kr 8.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Arcticzymes Technologies in your weekly email
Every Wednesday you see whether Arcticzymes Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing.
Show more
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Stock analysis
Arcticzymes Technologies ASA (AZT) currently trades at kr 20.30, while our model-based Fair Value estimate is kr 8.52, implying the stock looks roughly 138.3% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 7.92 per share, and 0 of the 24 models we run sit above the kr 20.30 price.
Bear case: the Earnings-Based group reads lowest at kr 1.62, and 24 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: kr 7.80 (bear) to kr 9.44 (bull), the price of kr 20.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Arcticzymes Technologies ASA reported revenue of 113M NOK in FY2025 versus 128M NOK in FY2021, a compound −3.1%/yr. Reported net income was 9.9M NOK in FY2025, compounding −32.1%/yr from FY2021.
Key figures
Market cap 1.0B NOK (≈ $109M) · P/E ratio 78.1 · P/S ratio 6.85 · EPS (TTM) kr 0.2600 · Net margin 8.8% · Return on equity 4.1% · Return on assets (EBIT) 7.4% · Operating margin −2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −58%, AZT screens richer than that median.
Fair Value models
Bear kr 7.80Fair Value kr 8.52Bull kr 9.44
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (kr 0.1909 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+7.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.8%
Start year 2020 (pandemic). Over 10 years: +7.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−31.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.46% → 3%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Norway: IMF forecast 2.4% a year to 2030, 3.3% from 2016 to 2025) that is about +22.7% a year for the price.
Compare Arcticzymes Technologies ASA with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside−59% · Below median
Profitability
Return on equity (TTM)4% · Above median
Return on assets1% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)−2% · Below median
Growth and dividend
Revenue growth41% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)78.1× · Priciest 25%
P/B3.15× · Pricier than median
P/S (TTM)8.32× · Pricier than median
P/FCF5.1× · Cheaper than median
EV/EBITDA74.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)16· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Arcticzymes Technologies ASA (AZT) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of kr 8.52 versus a price of kr 20.30, about −58% upside (overvalued).
What is the fair value of AZT?
Our model-based fair value for Arcticzymes Technologies ASA is kr 8.52 (as of Sep 24, 2026), built from audited fundamentals. The current price: kr 20.30.
What is the quality score of AZT?
Arcticzymes Technologies ASA has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arcticzymes Technologies ASA (AZT)?
Our model-based price target is the fair value of kr 8.52 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario kr 7.80, optimistic scenario kr 9.44. It is a calculation from audited fundamentals, not an analyst target.
What is the Arcticzymes Technologies ASA stock forecast for 2026?
Our models put fair value at kr 8.52, about −58% upside versus a price of kr 20.30 (overvalued). Cautious scenario kr 7.80, optimistic scenario kr 9.44. The calculation is refreshed regularly with new filings.
What is the revenue of Arcticzymes Technologies ASA (AZT)?
Arcticzymes Technologies ASA reported trailing-twelve-month revenue of about 128M NOK (latest available figure, as of Sep 24, 2026).
What growth is priced into Arcticzymes Technologies ASA (AZT)?
For today's price to be fair in a discounted-cash-flow model, Arcticzymes Technologies ASA would have to grow free cash flow by +25.6 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of AZT use?
Our models discount Arcticzymes Technologies ASA at 11.1 %: a base by market capitalisation (micro), damped by beta 0.55, country premium for Norway. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Arcticzymes Technologies ASA that is +25.6 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Arcticzymes Technologies ASA (AZT) delivered so far?
Over the past 5 years revenue at Arcticzymes Technologies ASA grew +3.8 % a year. The price currently implies +25.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Arcticzymes Technologies ASA (AZT) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Arcticzymes Technologies ASA (+25.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Arcticzymes Technologies ASA (AZT)?
The free-cash-flow yield on the price is 2.14 %: that much free cash flow Arcticzymes Technologies ASA produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Arcticzymes Technologies ASA (AZT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arcticzymes Technologies ASA it is kr 8.52 per share (as of Sep 24, 2026), against a price of kr 20.30. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Arcticzymes Technologies ASA stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AZT trades above its calculated fair value: price kr 20.30, fair value kr 8.52, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AZT?
No. The price is what the market pays today (kr 20.30); the fair value is what the company's own numbers justify (kr 8.52). For Arcticzymes Technologies ASA the two are kr 11.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Arcticzymes Technologies ASA worth?
The market values Arcticzymes Technologies ASA at about 1.0B NOK (market capitalisation, as of Sep 24, 2026). Per share that is kr 20.30; our models calculate a fair value of kr 8.52 per share.
What do the bullish and bearish scenarios say about AZT?
Our models span a range for Arcticzymes Technologies ASA: cautious scenario kr 7.80, base kr 8.52, optimistic kr 9.44 per share (as of Sep 24, 2026, price kr 20.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AZT?
Arcticzymes Technologies ASA trades at a price-to-earnings ratio of 78.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 8.52 is built from several models across several years. Other multiples: P/B 3.2, P/S 8.3, EV/EBITDA 74.9.
How solid is the balance sheet of Arcticzymes Technologies ASA (AZT)?
Balance-sheet figures for Arcticzymes Technologies ASA (as of Sep 24, 2026): return on equity 4.1%. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is AZT from its 52-week high?
Arcticzymes Technologies ASA trades at kr 20.30, about 34% below its 52-week high of kr 30.90 and 9% above the low of kr 18.65 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 8.52 is for.
Which stocks are comparable to Arcticzymes Technologies ASA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arcticzymes Technologies ASA stock attractive at the current price?
The data as of Sep 24, 2026: price kr 20.30, calculated fair value kr 8.52 (−58%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AZT calculated?
We run Arcticzymes Technologies ASA through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 8.52, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Arcticzymes Technologies ASA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arcticzymes Technologies ASA (AZT)?
The closing price on Sep 24, 2026 was kr 20.30. Our model-based fair value is kr 8.52, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arcticzymes Technologies ASA right now?
The price sits above even our optimistic bull case (kr 9.44). The favourable scenario is already priced in. Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Arcticzymes Technologies ASA
How large is the market capitalisation of Arcticzymes Technologies ASA (AZT)?
The market capitalisation of Arcticzymes Technologies ASA is 1.0B NOK (≈ $109M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arcticzymes Technologies ASA (AZT)?
The price-to-sales ratio of Arcticzymes Technologies ASA is 6.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arcticzymes Technologies ASA (AZT)?
Earnings per share at Arcticzymes Technologies ASA are kr 0.2600 (price ÷ EPS = P/E 78.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Arcticzymes Technologies ASA (AZT)?
The net margin of Arcticzymes Technologies ASA is 8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arcticzymes Technologies ASA (AZT)?
The return on equity (ROE) of Arcticzymes Technologies ASA is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arcticzymes Technologies ASA (AZT)?
On an EBIT basis the return on assets of Arcticzymes Technologies ASA is 7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arcticzymes Technologies ASA (AZT)?
The operating margin of Arcticzymes Technologies ASA is −2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arcticzymes Technologies ASA (AZT)?
Revenue at Arcticzymes Technologies ASA is growing +40.9% versus a year earlier (3y avg −6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arcticzymes Technologies ASA (AZT)?
Earnings per share at Arcticzymes Technologies ASA are growing +70.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Arcticzymes Technologies ASA (AZT) hold?
Arcticzymes Technologies ASA holds more cash than debt, 181M NOK net (fiscal year 2021). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Arcticzymes Technologies ASA in the live analysis
One click puts Arcticzymes Technologies ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
